Breakthrough cancer medicine and its impact on novel drug development in China:report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting
Feng Roger Luo Ge Zhang Li Xu Pascal Qian Li Yan Jian Ding Helen X. Chen Hao Liu Man-Cheong Fung Maria Koehler Jean Pierre Armand Lei Jiang Xiao Xu
癌症(英文版)Issue(12):620-624,5.
癌症(英文版)Issue(12):620-624,5.DOI:10.5732/cjc.014.10246
Breakthrough cancer medicine and its impact on novel drug development in China:report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting
Breakthrough cancer medicine and its impact on novel drug development in China:report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting
摘要
关键词
Breakthrough/clinical trial/cancer medicineKey words
Breakthrough/clinical trial/cancer medicine引用本文复制引用
Feng Roger Luo,Ge Zhang,Li Xu,Pascal Qian,Li Yan,Jian Ding,Helen X. Chen,Hao Liu,Man-Cheong Fung,Maria Koehler,Jean Pierre Armand,Lei Jiang,Xiao Xu..Breakthrough cancer medicine and its impact on novel drug development in China:report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting[J].癌症(英文版),2014,(12):620-624,5.基金项目
The authors would like to thank Dr. Pascal Qian and al Executive Members of USCACA for their contributions to the session and this report ()